create a cryptocurrency, People searches

The Ministry of National Defense responded to the question of whether to engage in exercises: the situation is unpredictable, and the leader of the Taiwan Province region, Lai Qingde, recently "transited" Hawaii and Guam. On the morning of December 13th, Senior Colonel Wu Qian, Director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, answered a reporter's question on whether the PLA would conduct exercises. A: It is the sacred duty of the People's Liberation Army to safeguard national sovereignty and territorial integrity, the fundamental interests of the Chinese nation and the common interests of compatriots on both sides of the strait. Soldiers have no constant potential and water is impermanent. Whether and when to hold the exercise is up to us to decide independently according to our own needs and the struggle situation. No matter whether the exercise is held or not, the PLA will not be absent or soft in fighting for "independence" and promoting reunification. Any act of "seeking independence by relying on foreign countries" and "seeking independence by force" will be severely punished and doomed to failure.The first-phase factory construction project of Aidi Precision (Thailand) started. According to Aidi Precision, in order to better lay out the global market, on December 12, Aidi Precision's first overseas manufacturing factory, Aidi Precision (Thailand), officially started construction. The construction project of Aidi Precision (Thailand) Factory, with a total investment of 35 million US dollars, covers an area of 122 mu and a workshop area of about 60,000 square meters. It will be engaged in the production, manufacture and sales of high-end hydraulic components and hydraulic fittings for construction machinery. The first phase of the project is scheduled to be completed and put into operation in October 2025.Pacific Securities: The reversal of photovoltaic industry is about to focus on three directions. The Pacific Securities Research Report pointed out that with the continuous breakthrough of new markets and technologies, the new cycle of photovoltaic parity is accelerating, and the reversal of photovoltaic industry is about to begin. It is suggested to focus on three directions: 1) The new cycle of supply and demand is expected to start in 2025, the industry quotation and profit are expected to be restored, and the leading advantages will be gradually highlighted. In 2025, it is expected to usher in a new round of growth, including Longji Green Energy and Jingke Energy. 2) New technology fields with large cost reduction space and continuous technology iteration, such as GCL Technology and Perovskite, are expected to fully benefit; 3) The advantages of supporting facilities and leading enterprises are prominent, and emerging markets are expected to promote the rapid improvement of shipments and profits, and the advantages of leading enterprises will be further enhanced, and enterprises such as Sunshine Power and Foster are expected to fully benefit.

Li Tie was sentenced to 20 years. On December 13, 2024, the Intermediate People's Court of Xianning City, Hubei Province publicly pronounced the case of Li Tie, the former head coach of China National Men's Football Team. Li Tie was sentenced to 20 years' imprisonment for accepting bribes, bribery, unit bribery, bribery of non-state staff and bribery of non-state staff. (CCTV News)Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)

Inter-bank cash bonds are strong as a whole, and national debt and CDB active bonds are down by 3-5bp. The 5-year treasury bonds and CDB active bonds went down by about 5bp, and "24 Treasury bonds with interest 20" reported 1.42%, which was a record low compared with yield to maturity, a Chinese bond in the same period, and "24 CDB 08" reported 1.515% in the same period, a record low since January 26th, 2006. The 10-year "24 interest-bearing treasury bonds 11" initially declined, and now it remains below 1.8%.List of stock repurchases of Hong Kong stocks: 43 stocks were repurchased by the company. On December 12, a total of 43 Hong Kong stocks were repurchased by the company, and the repurchase amount of 8 stocks exceeded HK$ 10 million. Among them, Tencent Holdings, AIA and Samsonite have the largest repurchase amounts, with the company repurchasing HK$ 704 million, HK$ 61,711,300 and HK$ 34,247,500 respectively. As of December 12, 274 Hong Kong stocks have been repurchased by the company this year, and the cumulative repurchase amount of 62 stocks during the year exceeded HK$ 100 million. Among them, Tencent Holdings, HSBC Holdings and AIA have the largest cumulative repurchase amount during the year, with the company repurchasing HK$ 104.602 billion, HK$ 40.706 billion and HK$ 31.059 billion respectively.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.